Get Ready for Hep C Meds Mavyret and Vosevi

October 2017

You'll see home med lists that include new oral hepatitis C Rxs, Mavyret and Vosevi.

Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.

It'll also be the lowest priced...about $26,400/course compared to $94,500 for Harvoni or $75,000 for Epclusa for 12 weeks.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Smoking Cessation Address Concerns About Nicotine Replacement Therapy
Opioids Be Ready to Help Explain Opioid Discharge Rx Limits to Patients
Med Administration Ensure Safe Peripheral Line Administration of Vasopressors and 3% Saline
Influenza Answer Your Patients' Questions About 2017-2018 Influenza Vaccination
Immunology Be Prepared to Treat Patients With Hereditary Angioedema
Beta-Blockers Help Switch Patients From Atenolol to a Better Beta-Blocker
Stroke Consider Pros and Cons of Switching Antiplatelets After a Breakthrough Stroke
Psychiatry Help Ensure PTSD Patients Are on the Right Treatment
New Drugs Keep Fluticasone Inhalers Straight During Transitions of Care
New Drugs Get Ready for Hep C Meds Mavyret and Vosevi
Help Patients Understand Treatments by Explaining Simple Statistical Terms

Get Ready for Hep C Meds Mavyret and Vosevi

Get unlimited access through an Enterprise license

Table of Contents